Armodafinil

From Wikipedia, the free encyclopedia

Armodafinil
Systematic (IUPAC) name
(-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide
Identifiers
CAS number 112111-43-0
ATC code N06BA07
PubChem 9690109
Chemical data
Formula C15H15NO2S 
Mol. mass 273.351
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism Hepatic, including CYP3A4 and other pathways
Half life 12-15 hrs
Excretion Urine (as metabolites)
Therapeutic considerations
Pregnancy cat.

C

Legal status

Schedule IV (USA)

Routes Oral

Armodafinil (Nuvigil) is a stimulant drug produced by the pharmaceutical company Cephalon Inc., which was approved by the FDA on June 15, 2007.[1]

Cephalon plans to conduct clinical trials evaluating the use of Nuvigil as a treatment for serious medical conditions such as bipolar depression, cognition associated with schizophrenia, and excessive sleepiness and fatigue in conditions such as Parkinson's disease and cancer.[2]

Nuvigil is protected by a U.S. patent expiring in 2023 that claims the Form 1 polymorph of armodafinil.

[edit] See also

[edit] References

  1. ^ CDER Drug and Biologic Approvals for Calendar Year 2007. Retrieved on 2008-01-21.
  2. ^ Cephalon - Pipeline,. Retrieved on 2008-01-21.
Languages